Showing 901-910 of 1635 results for "".
- Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi Inc.https://modernod.com/news/eyenovia-announces-rebranding-and-corporate-name-change-to-hyperion-defi-inc/2482871/Eyenovia announced a rebrand to Hyperion DeFi Inc., signaling a pivot toward decentralized finance. The rebranding reflects Hyperion DeFi’s cryptocurrency treasury reserve strategy, centered around HYPE, the native token of the Hyperliquid block
- Navigate Patient Solutions Adds Ophthalmology Leaders to its Medical Advisory Boardhttps://modernod.com/news/navigate-patient-solutions-adds-ophthalmology-leaders-to-its-medical-advisory-board/2482835/Navigate Patient Solutions announced the addition of Vance Thompson, MD; David Cox, and Matthew P. Jensen to its Medical Advisory Board. Navigate is developing a patient engagement solution for ophthalmology. The startup partners with ophthal
- NASA Astronauts to Headline Heidelberg Engineering’s 2025 International Spectralis Symposiumhttps://modernod.com/news/nasa-astronauts-to-headline-heidelberg-engineerings-2025-international-spectralis-symposium/2482818/Heidelberg Engineering announced that NASA astronauts Warren Hoburg and Tyson Brunstetter, OD, PhD, will lead the keynote presentation at the company’s
- Alon Harris, MS, PhD, Named 2025 Recipient of Robert Ritch Award for Innovation and Excellence in Glaucomahttps://modernod.com/news/alon-harris-named-2025-recipient-of-robert-ritch-award-for-innovation-and-excellence-in-glaucoma/2482778/Alon Harris, MS, PhD, FARVO, has been announced as the 2025 recipient of The Glaucoma Foundation’s (TGF) 'Robert Ritch Award for Innovation and Excellence in Glaucoma.' The award, established in 2008 and named after TGF founder Robert Ritch, MD, honor
- Nanoscope to Present New Data for Optogenetic Therapy for RP at Eyecelerator and ARVOhttps://modernod.com/news/nanoscope-to-present-new-data-for-optogenetic-therapy-for-rp-at-eyecelerator-and-arvo/2482769/Nanoscope Therapeutics announced participation at both the Eyecelerator and The Association for Research and Vision in Ophthalmology (ARVO) 2025 annual meetings. Nanoscope’s presentations will be centered around 126-week outcomes following treatment with its MCO-010
- Nacuity Pharmaceuticals Granted FDA Fast Track Designation for NPI-001 Tablets for RPhttps://modernod.com/news/nacuity-pharmaceuticals-granted-fda-fast-track-designation-for-npi-001-tablets-for-retinitis-pigmentosa/2482625/Nacuity Pharmaceuticals announced that the FDA has granted Fast Track Designation to NPI-001 (N-acetylcysteine amide) tablets, Nacuity’s proprietary investigational therapy for the treatment of patients with retinitis pigmentosa (RP). A drug may receive Fast Track designation
- Formycon Receives EU Approval for Eylea Biosimilar FYB203 Under the Brand Names Ahzantive and Baiamahttps://modernod.com/news/formycon-receives-eu-approval-for-eylea-biosimilar-fyb203-under-the-brand-names-ahzantive-and-baiama/2482624/Formycon and its licensing partner Klinge Biopharma jointly announce that the European Commission has granted central marketing authorization for FYB203 (aflibercept), a biosimilar to Eylea, under the brand names Ahzantive and Baiama. The app
- National Eye Institute Study Revisits Role of Annexin-V Biomarker in Retinal Cell Degenerationhttps://modernod.com/news/national-eye-institute-study-revisits-role-of-annexin-v-biomarker-in-retinal-cell-degeneration/2482588/Recent findings from a National Eye Institute-led study shed new light on annexin-V, a widely used biomarker to track apoptosis and retinal cell death in eye disease. The study group identified that annexin-V also binds to immune cells, suggesting it may a have a role as a marker for ocular infla
- Ocular Therapeutix Names Namrata Saroj as Chief Business Officerhttps://modernod.com/news/ocular-therapeutix-names-namrata-saroj-as-chief-business-officer/2482536/Ocular Therapeutix announced that Namrata Saroj, OD, has joined the company as Chief Business Officer (CBO). Dr. Saroj, who has been consulting with Ocular since February 2024, brings extensive experience in clinical development and commercialization in ophthalmology. She cont
- Nanoscope Therapeutics Plans to Submit BLA for Gene Therapy to Treat RPhttps://modernod.com/news/nanoscope-therapeutics-plans-to-submit-bla-for-gene-therapy-to-treat-retinitis-pigmentosa/2482476/Nanoscope Therapeutics has announced a successful meeting with the FDA regarding its lead clinical program, MCO-010, for the treatment of retinitis pigmentosa (RP). Following regulatory feedback from the FDA, the company plans to initiate a rolling submission of its biologics license ap